Application of ergothioneine in preparation of products for improving kidney health

Abstract

The invention relates to application of ergothioneine in preparation of a product for improving kidney health. The improvement of kidney health comprises any one or a combination of at least two of improvement of a kidney filtration function, reduction of kidney oxidative stress injury, improvement of urination discomfort and improvement of chronic kidney diseases. The invention develops a brand new application scene aiming at the ergothioneine, the ergothioneine has an excellent effect of improving and maintaining the kidney health, and further finds that the ergothioneine is combined with the L-theanine, the pyrroloquinoline quinone or the salt thereof to be used together, so that the ergothioneine has a more excellent effect in the aspect of improving the kidney health, and the three active ingredients promote each other, so that the effect of improving the kidney health is achieved. And an unexpected chain type synergistic effect can be obtained.

Description

Technical Field

[0001] This invention belongs to the field of nutritional intervention technology, specifically relating to the application of ergothionein in the preparation of products that improve kidney health. Background Technology

[0002] The clinical manifestations of chronic kidney disease (CKD) include proteinuria, hematuria, hypoalbuminemia, hypercholesterolemia, and edema. In addition, patients' renal function indicators also show elevated serum creatinine, decreased glomerular filtration rate, and elevated cystatin C (Cys C). The core of CKD management is early prevention and early treatment to avoid the onset of the disease and slow its progression. Currently, products on the market targeting CKD mainly focus on tonifying the kidneys, including single-ingredient precious medicinal herbs and health-preserving teas. Single-ingredient herbs include deer antler, cordyceps, epimedium, and cistanche, while health-preserving teas include ginseng, maca, and goji berry tea, and ginseng, polygonatum, and goji berry five-treasure tea. These products have very limited effectiveness in improving CKD, and their active ingredients are unclear.

[0003] The pathological progression of chronic kidney disease and early kidney injury involves renal microcirculatory disturbances, mitochondrial energy depletion, and persistent oxidative damage to DNA. Current dietary interventions often have the following limitations: While mitochondrial activators can induce the generation of new mitochondria in damaged kidney tissue, the high-intensity electron transport during the initial stages of energy metabolism remodeling can cause a transient surge in reactive oxygen species, resulting in oxidative stress damage to the kidneys. Furthermore, simply supplementing with antioxidants is insufficient to reverse the constriction and local ischemia of the afferent arterioles in the kidneys caused by chronic sympathetic hyperactivity. The high pressure and hypoxia in the microcirculation directly limit the effective delivery and accumulation of antioxidants to the renal tubular epithelial cells and glomerular podocytes. Moreover, current dietary interventions are ineffective in improving renal nocturia.

[0004] Therefore, developing a product that can overcome the shortcomings of the existing technology and improve renal microcirculation disorders, mitochondrial energy depletion, and continuous DNA oxidative damage has become an urgent technical problem to be solved in this field. Summary of the Invention

[0005] In view of the shortcomings of the prior art, the purpose of this invention is to provide the application of ergothionein in the preparation of products that improve kidney health.

[0006] To achieve this objective, the present invention adopts the following technical solution: In a first aspect, the present invention provides the use of ergothionein in the preparation of products that improve kidney health; The improvement of kidney health includes any one or a combination of at least two of the following: improving kidney filtration function, reducing kidney oxidative stress damage, improving urinary discomfort, and improving chronic kidney disease.

[0007] This invention develops a novel application scenario for ergothioneine, which has excellent effects on improving and maintaining kidney health. Specifically, it can improve kidney filtration function, reduce kidney oxidative stress damage, improve urinary discomfort, and improve chronic kidney disease.

[0008] Preferably, the product further includes excipients; the excipients include any one or a combination of at least two of the following: carrier, diluent, excipient, filler, binder, wetting agent, disintegrant, emulsifier, cosolvent, solubilizer, osmotic pressure regulator, surfactant, coating material, colorant, pH adjuster, antioxidant, antibacterial agent, or buffer.

[0009] Preferably, the dosage form of the product includes tablets, capsules, granules, powders, oral liquids, syrups, suspensions, dry suspensions, or pills.

[0010] Preferably, the active ingredient in the product is ergothioneine, L-theanine, pyrroloquinoline quinone, or a salt thereof.

[0011] The "pyrroloquinoline quinone or its salt" mentioned in this invention includes pyrroloquinoline quinone or pyrroloquinoline quinone disodium salt.

[0012] This invention also creatively discovers that combining the aforementioned ergothioneine with L-theanine, pyrrolquinone or their salts results in a superior effect on improving kidney health. Pyrrolquinone or its salts can induce the formation of new mitochondria in damaged kidney tissue. Ergothioneine, with its extremely high redox potential, specifically anchors to the inner membrane of newly formed mitochondria, neutralizing the free radical storm caused by pyrrolquinone or its salts, completely cutting off the attack of free radicals on nucleic acids, and resolving the toxicity risks associated with using pyrrolquinone or its salts alone. L-theanine can regulate the sympathetic nervous system, dilate the afferent arterioles of the kidney, and reduce systemic stress resistance. This "physical decompression" effect improves renal tubular blood perfusion and maintains the high activity of the energy-dependent transporter SLC22A4 / OCTN1 in low-pH filtrate conditions, enabling ergothioneine to target and accumulate in podocytes and renal tubules more efficiently to exert its effects. Simultaneously, L-theanine can alleviate the sensitivity of the bladder detrusor muscle, while ergothioneine can protect the electrolyte-sensitive ion pumps in the distal convoluted tubule of the kidney, maintaining the reabsorption balance of Na, K, and Cl. These three components work synergistically to achieve an unexpected chain-like synergistic effect, significantly superior to a single active ingredient or any combination of two active ingredients.

[0013] Preferably, the mass ratio of ergothioneine, L-theanine, pyrroloquinoline quinone or its salt is (0.5-75):(5-200):(1-10).

[0014] The specific point values ​​in (0.5-75) can be 0.5, 1, 3, 5, 8, 10, 20, 30, 40, 50, 60, 70, 75, etc.; the specific point values ​​in (5-200) can be 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, etc.; the specific point values ​​in (1-10) can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, etc.; other point values ​​within the above ranges can also be selected, and will not be elaborated on here.

[0015] Based on the unpredictable chain synergistic effect of ergothioneine, L-theanine, and pyrroloquinoline quinone or their salts, their effects on improving kidney health are enhanced when the specific mass ratios mentioned above are met.

[0016] In a second aspect, the present invention provides an efficacy composition for improving kidney health, wherein the active ingredients in the efficacy composition for improving kidney health include ergothioneine, L-theanine, pyrrolquinone or salts thereof.

[0017] This invention also developed a novel composition for improving kidney health, which combines three specific components: ergothioneine, L-theanine, and pyrroloquinoline quinone or their salts. Studies have found that the three components have a synergistic effect in improving kidney filtration function, reducing kidney oxidative stress damage, improving urinary discomfort, and improving chronic kidney disease.

[0018] Preferably, the mass ratio of ergothioneine, L-theanine, pyrroloquinoline quinone or its salt is (0.5-75):(5-200):(1-10).

[0019] The specific point values ​​in (0.5-75) can be 0.5, 1, 3, 5, 8, 10, 20, 30, 40, 50, 60, 70, 75, etc.; the specific point values ​​in (5-200) can be 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, etc.; the specific point values ​​in (1-10) can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, etc.; other point values ​​within the above ranges can also be selected, and will not be elaborated on here.

[0020] Based on the unpredictable chain synergistic effect of ergothioneine, L-theanine, pyrroloquinoline quinone or their salts, when the above-mentioned specific mass ratio is met, it has a better effect on improving renal filtration function, reducing renal oxidative stress damage, improving urinary discomfort, and improving chronic kidney disease.

[0021] Preferably, the functional composition further contains excipients; the excipients include any one or a combination of at least two of the following: carrier, diluent, excipient, filler, binder, wetting agent, disintegrant, emulsifier, cosolvent, solubilizer, osmotic pressure regulator, surfactant, coating material, colorant, pH adjuster, antioxidant, antibacterial agent, or buffer.

[0022] Thirdly, the present invention provides the use of the efficacy composition according to the second aspect in the preparation of products having any one or at least two of the following combined efficacies: 1) Improves kidney filtration function; 2) Reduces oxidative stress damage to the kidneys; 3) Improves urinary discomfort; 4) Improves chronic kidney disease.

[0023] Preferably, the dosage form of the product includes tablets, capsules, granules, powders, oral liquids, syrups, suspensions, dry suspensions, or pills.

[0024] Compared with the prior art, the present invention has the following beneficial effects: This invention develops a novel application scenario for ergothioneine, which has excellent effects on improving and maintaining kidney health. Specifically, it can improve kidney filtration function, reduce kidney oxidative stress damage, improve urinary discomfort, and improve chronic kidney disease.

[0025] Further investigation revealed that combining ergothioneine with L-theanine, pyrrolquinone, or their salts resulted in superior effects in improving kidney health. Pyrrolquinone or its salts induced the formation of new mitochondria in damaged kidney tissue. Ergothioneine, with its extremely high redox potential, specifically anchored itself to the inner membrane of newly formed mitochondria, neutralizing the free radical storm caused by pyrrolquinone or its salts, completely cutting off the attack of free radicals on nucleic acids, and resolving the toxicity risks associated with using pyrrolquinone or its salts alone. L-theanine, by regulating the sympathetic nervous system, dilated the afferent arterioles of the kidney, reducing systemic stress resistance. This "physical decompression" effect improved renal tubular blood perfusion and maintained the high activity of the energy-dependent transporter SLC22A4 / OCTN1 in low-pH filtrate conditions, enabling ergothioneine to target and accumulate in podocytes and renal tubules more efficiently to exert its effects. Meanwhile, L-theanine can alleviate the sensitivity of the bladder detrusor muscle, and ergothioneine can protect the electrolyte-sensitive ion pumps in the distal convoluted tubule of the kidney, maintaining the reabsorption balance of Na, K, and Cl. The three active ingredients promote each other, achieving an unexpected chain-like synergistic effect. Detailed Implementation

[0026] To further illustrate the technical means and effects of the present invention, the following describes the technical solution of the present invention in conjunction with preferred embodiments of the present invention. However, the present invention is not limited to the scope of the embodiments.

[0027] Ergothionein used in the embodiments and comparative examples of this application was provided by Jiangsu Jinsan Biotechnology Co., Ltd.; L-theanine was provided by Ningbo Hengyi Biotechnology Co., Ltd.; and disodium pyrroloquinoline quinone was provided by Zhucheng Haotian Pharmaceutical Co., Ltd.

[0028] Example 1 This embodiment provides an efficacy composition obtained by mixing ergothioneine, disodium pyrroloquinoline quinone, and L-theanine in a mass ratio of 3:1:20 at 25°C.

[0029] Example 2 This embodiment provides an efficacy composition obtained by mixing ergothioneine, disodium pyrroloquinoline quinone, and L-theanine in a mass ratio of 8:2:35 at 25°C.

[0030] Example 3 This embodiment provides an efficacy composition obtained by mixing ergothioneine, disodium pyrroloquinoline quinone, and L-theanine in a mass ratio of 10:3:50 at 25°C.

[0031] Example 4 This embodiment provides an efficacy composition obtained by mixing ergothioneine, disodium pyrroloquinoline quinone, and L-theanine in a mass ratio of 3:3:10 at 25°C.

[0032] Example 5 This embodiment provides an efficacy composition obtained by mixing ergothioneine, disodium pyrroloquinoline quinone, and L-theanine in a mass ratio of 0.5:4:10 at 25°C.

[0033] Comparative Example 1 This comparative example provides an efficacy composition that differs from Example 1 only in the absence of ergothioneine, with the reduced mass proportionally allocated to the mass of pyrroloquinoline quinone disodium salt and L-theanine.

[0034] Comparative Example 2 This comparative example provides an efficacy composition that differs from Example 1 only in the absence of pyrroloquinoline quinone disodium salt, with the reduced mass proportionally allocated to the mass of ergothioneine and L-theanine.

[0035] Comparative Example 3 This comparative example provides an efficacy composition that differs from Example 1 only in the absence of L-theanine, with the reduced mass proportionally allocated to the mass of ergothioneine and pyrroquinoline quinone disodium salt.

[0036] Comparative Example 4 This comparative example uses a single component, ergothioneine.

[0037] Comparative Example 5 This comparative example is a single-component disodium salt of pyrroloquinoline quinone.

[0038] Comparative Example 6 This comparative example uses a single component, L-theanine.

[0039] Test Example 1 Studies on the efficacy and safety of ergothionein in improving kidney health: 1. Research Plan (1) Research product: Ergothioneine capsules, EGT 30mg / capsule, 120 capsules / bottle, provided by Jiangsu Jinsan Biotechnology Co., Ltd.

[0040] (2) Dosage and administration: Take 2 capsules (30mg / capsule) twice a day for 90 consecutive days.

[0041] (3) Inclusion criteria for subjects: (3.1) Age 45 ≤ 70 years old, gender not limited; (3.2) At least one of the following conditions must be met: ①Estimated glomerular filtration rate: 45 ml / min / (1.73 m 2 )≤eGFR<59 ml / min / (1.73 m 2 And the urine albumin-to-creatinine ratio (UACR) is ≤30mg / g.

[0042] ② Estimate glomerular filtration rate: 60 ml / min / (1.73 m 2 )≤eGFR≤89 ml / min / (1.73 m 2 And the urine albumin-to-creatinine ratio (UACR) is ≤300mg / g.

[0043] ③ Estimate glomerular filtration rate (eGFR) ≥ 90 ml / min / (1.73 m 2 And the urine albumin-to-creatinine ratio is 30 mg / g ≤ (UACR) ≤ 300 mg / g.

[0044] (3.3) Those who experience symptoms such as frequent urination, urgency, dark urine color, increased urine foam, and soreness in the lower back and knees in daily life for ≥3 months; (3.4) Voluntarily sign the informed consent form before the start of the activities related to this study, understand the procedures and methods of this study, and are willing to strictly abide by the clinical trial study protocol.

[0045] No other drug treatments (including prescription and over-the-counter drugs) or non-drug treatments were used from one month prior to the trial until the end of the study.

[0046] (4) Experimental Methods: The trial participants were selected from individuals with abnormal renal function, with a total of 30 participants enrolled. After obtaining informed consent, participants underwent screening examinations. Qualified participants were randomly assigned numbers, and baseline levels were measured and the trial products were distributed. Participants used products with corresponding random numbers for 90 consecutive days, and their results were recorded in a diary. Renal function-related indicators were measured on the day of enrollment as baseline measurements, and on day 90 after enrollment, these indicators were measured again to evaluate the efficacy and safety of ergothioneine capsules in improving kidney health.

[0047] 2. Evaluation indicators: 2.1 Functional Indicators (1) Glomerular filtration rate (eGFR), urine albumin / creatinine ratio (UACR); (2) Renal function indicators: serum creatinine (CREA), urea (UREA), urinary microalbumin, uric acid (SUA), serum cystatin C; (3) Urine electrolyte level test: Na (sodium), K (potassium), Cl (chlorine); (4) Urinating status.

[0048] 2.2 Safety Indicators (1) Complete blood count, liver function, kidney function, urinalysis, and urine pregnancy test (female only); (2) All adverse events that occurred after the test product was received, and the incidence of adverse reactions during the test period was calculated.

[0049] 3. Evaluation results of functional indicators (1) The level of glomerular filtration rate (eGFR) was significantly improved. After 90 days of taking ergothioneine capsules, the mean glomerular filtration rate of the participants improved compared to before taking the capsules, which was 86.04 ± 17.89 mL / min / 1.73 m³ / min. 2 The mean value after administration was 93.25 ± 19.00 mL / min / 1.73m. 2 The improvement was 8.37%, which was statistically significant compared with before administration (p < 0.01).

[0050] Based on these results, continuous administration of ergothioneine capsules for 3 months can significantly enhance glomerular filtration capacity and improve the kidney's efficiency in clearing metabolic waste.

[0051] (2) The urine albumin / creatinine ratio (UACR) shows an improving trend. After taking ergothioneine capsules for 90 days, the mean urine albumin / creatinine ratio of the participants improved compared with before taking the capsules. The mean before taking the capsules was 78.84±88.28 mg / g, and the mean after taking the capsules was 67.58±89.24 mg / g, which was an improvement of 14.29% compared with before taking the capsules.

[0052] The above results indicate that ergothioneine capsules can effectively reduce protein leakage from the renal filtration membrane, decrease the protein load in the renal mesangial area and renal tubules, and reduce renal tissue damage caused by protein deposition, demonstrating outstanding potential renal protective efficacy.

[0053] (3) Improvement in renal function indicators After taking ergothioneine capsules for 90 days, the mean serum creatinine level of the participants improved from 85.56 μmol / L to 79.60 μmol / L, an improvement of 6.97%, which was statistically significant compared with the level before taking the capsules (p < 0.05). The results indicate that ergothioneine capsules have a significant positive regulatory effect on renal excretion function.

[0054] The average urea level improved from 6.80 μmol / L to 6.29 μmol / L, an improvement of 7.47% compared with before administration. This is highly consistent with the overall trend of improved renal function, forming a dual verification of improved filtration and excretion functions.

[0055] The urinary microalbumin level improved by 29.55% compared to before administration, indicating that ergothioneine capsules help reduce the burden of protein filtration and slow down the progression of kidney damage caused by protein deposition.

[0056] Serum cystatin C, uric acid, and other auxiliary indicators of renal function remained stable throughout the experiment without any abnormal fluctuations, suggesting that ergothioneine capsules have a mild regulatory effect on the kidneys and do not interfere with their basal metabolic function.

[0057] (4) Stable urine electrolytes After 90 days of taking ergothioneine capsules, the participants in the trial showed no significant changes in mean urinary potassium, urinary chloride, and urinary sodium levels compared to before taking the capsules. This indicates that while ergothioneine capsules improve renal function, they do not interfere with the renal tubular reabsorption and excretion of electrolytes, thus helping to maintain electrolyte balance and homeostasis.

[0058] (5) Improved urination Participants were asked about their subjective feelings regarding urination, frequency of urination, urine characteristics, and lower back pain to assess whether there had been any improvement in urination. The questionnaire is shown in the table below: After 90 days of taking ergothioneine capsules, the mean total score of voiding assessment in the participants was significantly lower than before treatment. The mean score before treatment was 13.67±6.19, and the mean score after treatment was 5.85±3.69, an improvement of 57.18%, which was statistically significant (p<0.001). Regarding specific symptoms, after 90 days of continuous use, the core complaints of patients, such as "interval between urinations less than two hours (urinary frequency)" and "inability to wait for urination (urinary urgency)," were effectively relieved, with scores significantly decreasing by 60.58% and 74.12% respectively compared to before treatment (P<0.05 and P<0.01). Furthermore, the sign of "increased urine foam," which strongly suggests impaired glomerular filtration function, also showed significant improvement with the total score, decreasing by 44.57% compared to before treatment (P<0.05). In conclusion, these results indicate that ergothioneine capsules can significantly relieve urination-related discomfort symptoms such as urinary frequency and urgency in the participants.

[0059] Participants who took ergothioneine capsules for 90 days showed a significant decrease in their mean VAS score for low back pain compared to before treatment. The mean score before treatment was 2.26±1.75, and the mean score after treatment was 0.74±0.66, representing an improvement of 67.21%, which was statistically significant (p<0.001). These results indicate that ergothioneine capsules can significantly reduce the severity of low back pain, effectively improve the quality of life of the participants, and the effect increases with the duration of intervention.

[0060] (4) Safety evaluation indicators During the trial, no abnormalities were observed in the safety indicators of the participants, and no adverse reactions related to the test product were observed. This fully demonstrates that ergothioneine capsules exhibit excellent safety performance under the current study design.

[0061] Test Example 2 Evaluation of the efficacy composition in improving kidney health: (1) Test samples: The products of Examples 1-5 and Comparative Examples 1-6 were respectively added to 0.5% CMC-Na solution to prepare suspensions for later use.

[0062] (2) Experimental animals: 140 healthy male C57BL / 6J mice were acclimatized for 1 week. They were randomly divided into 14 groups (10 mice in each group): blank control group, model group, positive drug group (dapagliflozin 1 mg / kg + allopurinol 5 mg / kg), Example 1-5 groups, and comparative examples 1-6 groups.

[0063] (3) Animal model construction: Except for the blank control group, the other groups were treated with "potassium oxonate (250 mg / kg) combined with adenine (50 mg / kg) by gavage, plus a high-fat diet" for 8 consecutive weeks to establish a subclinical glomerular lesion model with hyperuricemia.

[0064] (4) Intervention plan: Starting from week 5 of modeling, mice in each group were administered different experimental samples via gavage daily. The gavage doses for mice in Example 1 group were: ergothioneine 15 mg / kg, pyrrolquinone disodium salt 5 mg / kg, and L-theanine 100 mg / kg. The total intervention weight for Examples 2-5 and Comparative Examples 1-3 was the same as that for Example 1 group. The gavage doses for Comparative Examples 4-6 were: ergothioneine 15 mg / kg, pyrrolquinone disodium salt 5 mg / kg, and L-theanine 100 mg / kg, respectively. The positive control group was administered dapagliflozin 1 mg / kg + allopurinol 5 mg / kg daily via gavage. The blank control group and the model group were administered the same volume of physiological saline as in Example 1 group daily via gavage.

[0065] Detection indicators and their detection methods: (5.1) Urinary albumin / creatinine ratio (UACR) Sample collection: Mice were placed individually in metabolic cages, and 24-hour continuous urine was collected at the end of week 8. After collection, the urine was centrifuged at 2000 r / min for 10 minutes at 4°C to remove impurities, and the supernatant was aliquoted and frozen at -80°C for later use.

[0066] Detection of urinary microalbumin (mAlb): A specific mouse albumin-linked immunosorbent assay (ELISA) kit was used. The sample addition, plate washing, addition of enzyme-labeled antibody and color development were strictly performed in accordance with the instructions. The absorbance was read at a wavelength of 450 nm using an ELISA reader and the concentration was calculated according to the standard curve.

[0067] Urine creatinine (Ucr) detection: Colorimetric determination was performed using a creatinine detection kit (sarcosine oxidase method or picric acid method).

[0068] Calculation formula: UACR (mg / g) = Urinary microalbumin concentration (mg / L) / Urinary creatinine concentration (g / L).

[0069] (5.2) Endogenous creatinine clearance rate (Ccr) Data acquisition: The 24-hour urine volume (V, mL), urine creatinine concentration (Ucr, μmol / L), and serum creatinine concentration (Scr, μmol / L) were acquired simultaneously.

[0070] The calculation formula is: Endogenous creatinine clearance rate Ccr (mL / min) = [urinary creatinine concentration (Ucr) × 24-hour urine volume (V)] ÷ [serum creatinine concentration (Scr) × 1440 minutes]. This indicator is used to objectively characterize the glomerular filtration rate (eGFR) level in mice.

[0071] (5.3) Urinary 8-hydroxydeoxyguanosine (8-OHdG) Sample processing: Take the 24-hour urine supernatant collected above. Since 8-OHdG is a trace metabolite of DNA oxidative damage, repeated freeze-thaw cycles should be avoided.

[0072] Detection Procedure: A highly sensitive mouse 8-OHdG competitive ELISA kit was used. Standards and diluted urine samples were added to microplates pre-coated with 8-OHdG antibody. A biotinylated competitive antigen was added to initiate a competitive binding reaction. After washing, horseradish peroxidase (HRP)-labeled avidin was added, and the sample was developed using TMB substrate. After the reaction was terminated, the OD value was measured at 450 nm using a microplate reader. The concentration of 8-OHdG in the sample is inversely proportional to the OD value; the precise concentration was calculated by fitting a standard curve using a four-parameter logic function (4-PL).

[0073] (6) Evaluation results Table 1 As shown in Table 1, the composition involved in this invention exhibits excellent efficacy in reversing subclinical renal injury caused by hyperuricemia. The composition with the preferred ratio (Examples 1-3) is even more effective. The preferred ratio group can restore the endogenous creatinine clearance rate (Ccr) to 0.35-0.37 mL / min, and at the same time reduce the urine albumin / creatinine ratio (UACR) from 162.4 mg / g in the model group to 58.5-72.4 mg / g, effectively inhibiting the early mild to moderate protein leakage phenomenon.

[0074] Table 2 Table 2 data visually demonstrates the remarkable efficacy of the compositions involved in this invention in targeting and defending against cellular ultrastructural damage. In the model group, long-term high uric acid and metabolic abnormalities triggered severe oxidative stress, leading to a surge in urinary 8-OHdG (a core marker of DNA oxidative damage) to 59.4 ng / mL. After intervention with the compositions of this invention, especially the preferred formulations (Examples 1-3), this index was suppressed to between 33.6 and 36.8 ng / mL (P<0.001).

[0075] Based on the in vivo animal experimental data in Tables 1 and 2 above, it can be seen that the composition of ergothioneine, pyrroloquinoline quinone (PQQ) or its salts and L-theanine of the present invention exhibits a highly innovative synergistic effect in improving kidney health.

[0076] The applicant declares that the technical solution of this invention is illustrated by the above embodiments, but this invention is not limited to the above embodiments, that is, it does not mean that this invention must rely on the above embodiments to be implemented. Those skilled in the art should understand that any improvements to this invention, equivalent substitutions of raw materials for the product of this invention, addition of auxiliary components, and selection of specific methods, etc., all fall within the protection scope and disclosure scope of this invention.

[0077] The preferred embodiments of the present invention have been described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the scope of the technical concept of the present invention, various simple modifications can be made to the technical solution of the present invention, and these simple modifications all fall within the protection scope of the present invention.

[0078] It should also be noted that the various specific technical features described in the above specific embodiments can be combined in any suitable manner without contradiction. In order to avoid unnecessary repetition, the present invention will not describe the various possible combinations separately.

Claims

1. Application of ergothioneine in the preparation of products that improve kidney health; The improvement of kidney health includes any one or a combination of at least two of the following: improving kidney filtration function, reducing kidney oxidative stress damage, improving urinary discomfort, and improving chronic kidney disease.

2. The application according to claim 1, characterized in that, The product also includes excipients; the excipients include any one or a combination of at least two of the following: carrier, diluent, excipient, filler, binder, wetting agent, disintegrant, emulsifier, cosolvent, solubilizer, osmotic pressure regulator, surfactant, coating material, colorant, pH adjuster, antioxidant, antibacterial agent or buffer.

3. The application according to claim 1, characterized in that, The dosage forms of the products include tablets, capsules, granules, powders, oral liquids, syrups, suspensions, dry suspensions, or pills.

4. The application according to any one of claims 1-3, characterized in that, The active ingredients in the product are ergothioneine, L-theanine, pyrroloquinoline quinone, or their salts.

5. The application according to claim 4, characterized in that, The mass ratio of ergothioneine, L-theanine, pyrroloquinoline quinone or their salts is (0.5-75):(5-200):(1-10).

6. A composition for improving kidney health, characterized in that, The active ingredients in the composition for improving kidney health include ergothioneine, L-theanine, pyrrolquinone, or their salts.

7. The efficacy composition according to claim 6, characterized in that, The mass ratio of ergothioneine, L-theanine, pyrroloquinoline quinone or their salts is (0.5-75):(5-200):(1-10).

8. The efficacy composition according to claim 6 or 7, characterized in that, The efficacy composition also contains excipients; the excipients include any one or a combination of at least two of the following: carrier, diluent, excipient, filler, binder, wetting agent, disintegrant, emulsifier, cosolvent, solubilizer, osmotic pressure regulator, surfactant, coating material, colorant, pH adjuster, antioxidant, antibacterial agent or buffer.

9. The use of the efficacy composition according to any one of claims 6-8 in the preparation of a product having any one or at least two of the following combined efficacies: 1) Improves kidney filtration function; 2) Reduces oxidative stress damage to the kidneys; 3) Improves urinary discomfort; 4) Improves chronic kidney disease.

10. The application according to claim 9, characterized in that, The dosage forms of the products include tablets, capsules, granules, powders, oral liquids, syrups, suspensions, dry suspensions, or pills.

Images